As for the relationship between serum β2M levels and CVEs, a cohort study in the SPRINT trial recruited 2377 CKD patients, and found that serum β2M levels were not associated with the rate of CVEs [23], which was consistent with our results. This evidence concerns the gene B2M and chronic kidney disease.